{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
moxifloxacin
to a specific field?
Status:
Other
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
Octaplasma by Octapharma Pharmazeutika Produktionsges M B H [Canada]
Source URL:
First approved in 2013
Source:
BLA125416
Source URL:
Class:
MIXTURE
Status:
Investigational
Source:
NCT03820076: Not Applicable Interventional Completed Study of Three Doses of AZT-04 for Skin Appearance
(2019)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT02116998: Phase 2 Interventional Completed Pneumococcal Infections
(2014)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03918629: Phase 3 Interventional Completed Clostridium Difficile Associated Disease
(2019)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2012)
Source URL:
First approved in 2012
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
